-
PPMD 2024: PTC to seek FDA approval of ataluren for DMD
PTC Therapeutics plans to soon ask the U.S. Food and Drug Administration (FDA) to approve […]
-
PPMD 2024: DMD therapies to boost dystrophin advance in trials
More than half a dozen exon-skipping therapies for Duchenne muscular dystrophy (DMD) — all seeking […]
-
Protected: Duchenne Bone Health Study
This content is password protected. To view it please enter your password below: Password: The […]
-
PPMD 2024: Conference keynote address recalls 30 years of advocacy
Parent Project Muscular Dystrophy (PPMD) held its first conference in 1994, in Orlando, Florida. A […]
-
When did I stop being a fun mom for my children?
“I didn’t think you’d jump with us,” said my daughter Mary, 9, breathing heavily as […]
-
Capricor Therapeutics Announces Positive Skeletal Muscle and Cardiac Function Data from HOPE-2 OLE Study Data of Deramiocel (CAP-1002)
Capricor Therapeutics today announced additional positive 3-year safety and efficacy results from the company’s ongoing […]
-
PPMD 2024: 30 years of ‘progress, community, and resilience’
The Parent Project Muscular Dystrophy (PPMD) 30th annual conference kicks off today, offering families affected […]
-
Upcoming Capricor, FDA meeting to focus on DMD treatment deramiocel
Capricor Therapeutics will soon meet with the U.S. Food and Drug Administration (FDA) to discuss […]
-
Study of LGMD2i therapy BBP-418 exceeds interim analysis enrollment
A Phase 3 trial testing an experimental therapy for limb-girdle muscular dystrophy type 2i (LGMD2i) has […]
-
PPMD Convenes Leading Experts to Discuss Topics in Becker Care Ahead of 30th Annual Conference
Leading into PPMD’s 30th Annual Conference, PPMD is excited to host a professional meeting focusing […]
